Gemphire Therapeutics to Present Corporate Overview at the Ladenburg Thalmann 2016 Healthcare Conference

LIVONIA, Mich., Sept. 22, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (Nasdaq:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and NAFLD/NASH (nonalcoholic fatty liver disease), today announced that Mina Sooch, President and Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2016 Healthcare Conference, being held at the Sofitel New York Hotel, on Tuesday, September 27.

Presentation Details:
Date:Tuesday, September 27
Time: 2:00pm Eastern Time
Location: Sofitel New York Hotel, Trocadero Room

The presentation slides will be available immediately prior to and for 90 days following the presentation on the Investors and Media page of Gemphire’s website at http://ir.gemphire.com.

About Gemphire
Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and NAFLD/NASH (nonalcoholic fatty liver disease). Please visit www.gemphire.com for more information.

Contact: Andrew McDonald, Ph.D. LifeSci Advisors, LLC (646) 597-6987 Jeff Mathiesen, CFO Gemphire Therapeutics (734)-245-1700

Source:Gemphire Therapeutics